Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Go back to Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus
(NASDAQ: MIRM) Delayed: 80.39 -2.71 (3.26%)
Previous Close $83.10    52 Week High $ 
Open $82.39    52 Week Low $ 
Day High $83.00    P/E N/A 
Day Low $80.24    EPS $ 
Volume 788,216